The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pretreatment and postresection epidermal growth factor receptor (EGFR) pathway mutations in a prospective phase II trial (EXCITE) of preoperative cetuximab-containing chemoradiation (CRT) in locally advanced rectal cancer (LARC).
Simon Gollins
Honoraria - Roche
Research Funding - Merck Serono
Philip Quirke
No relevant relationships to disclose
Sun Myint
No relevant relationships to disclose
Mark P. Saunders
No relevant relationships to disclose
David Sebag-Montefiore
No relevant relationships to disclose
Shabbir Susnerwala
No relevant relationships to disclose
Sharadah Essapen
No relevant relationships to disclose
Leslie M. Samuel
No relevant relationships to disclose
Bruce Sizer
No relevant relationships to disclose
Sandy Beare
No relevant relationships to disclose
Lawrie Emma
No relevant relationships to disclose
Mark Jitlal
No relevant relationships to disclose
Nicholas West
No relevant relationships to disclose